Active Biotech — Board/Management Information 2008

Nov 28, 2008

Active Biotech's election committee appointed

In accordance with the decision by the Annual General Meeting on May 7, 2008, the election committee shall consist of representatives from the three largest shareholders as at the end of October and the Chairman of the Board.

The election committee for the next Board election consists of Johnny Sommarlund for MGA Holding, Tomas Billing for Nordstjernan and Ulf Strömsten for Catella funds.

Headed by the Chairman of the Board, Mats Arnhög, the election committee will prepare a proposal for the composition of the Board to be presented to the Annual General Meeting on May 7, 2009.

Lund, November 28, 2008 Active Biotech AB (publ)

Tomas Leanderson President and CEO

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on November 28, 2008, at 10:30 a.m.

Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46-19 20 00 Fax: +46 46-19 11 00 www.activebiotech.com